Amarillo Biosciences (OTCMKTS:AMAR – Get Free Report) and Eastman Kodak (NYSE:KODK – Get Free Report) are both small-cap technology companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership and dividends.
Volatility & Risk
Amarillo Biosciences has a beta of -0.06, indicating that its share price is 106% less volatile than the S&P 500. Comparatively, Eastman Kodak has a beta of 1.56, indicating that its share price is 56% more volatile than the S&P 500.
Earnings and Valuation
This table compares Amarillo Biosciences and Eastman Kodak”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Amarillo Biosciences | $20,000.00 | 0.00 | -$1.45 million | N/A | N/A |
| Eastman Kodak | $1.07 billion | 0.92 | -$128.00 million | ($1.39) | -7.21 |
Amarillo Biosciences has higher earnings, but lower revenue than Eastman Kodak.
Analyst Ratings
This is a summary of current recommendations and price targets for Amarillo Biosciences and Eastman Kodak, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Amarillo Biosciences | 0 | 0 | 0 | 0 | 0.00 |
| Eastman Kodak | 1 | 0 | 0 | 0 | 1.00 |
Given Amarillo Biosciences’ higher probable upside, research analysts clearly believe Amarillo Biosciences is more favorable than Eastman Kodak.
Institutional and Insider Ownership
33.6% of Eastman Kodak shares are owned by institutional investors. 34.4% of Amarillo Biosciences shares are owned by company insiders. Comparatively, 21.3% of Eastman Kodak shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Profitability
This table compares Amarillo Biosciences and Eastman Kodak’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Amarillo Biosciences | -41,453.98% | N/A | -574.29% |
| Eastman Kodak | -8.28% | -14.47% | -5.55% |
Summary
Eastman Kodak beats Amarillo Biosciences on 6 of the 10 factors compared between the two stocks.
About Amarillo Biosciences
Amarillo Biosciences, Inc., a healthcare company, engages in the discovery and development of pharmaceutical and biotech products in the United States and Asia. The company operates in three divisions: Pharmaceutical, Medical, and Consumer. The Pharmaceutical division offers low-dose non-injectable interferon (IFN) for the treatment of neoplastic, viral, and fibrotic diseases. The Medical division focuses on medical devices and developing technology to treat metabolism related diseases, such as Type 1 and Type 2 diabetes. The Consumer division provides a range of nutraceutical and food supplement products that utilize a liposomal delivery system. It owns four issued patents related to the low-dose oral delivery of interferon; one patent is for a product promoting oral health; and three patents are associated with treatment of metabolic disorders. The company was incorporated in 1984 and is based in Amarillo, Texas.
About Eastman Kodak
Eastman Kodak Company engages in the provision of hardware, software, consumables, and services to customers in the commercial print, packaging, publishing, manufacturing, and entertainment markets worldwide. The company operates through three segments: Print, Advanced Materials and Chemicals, and Brand. The Print segment provides digital offset plate offerings and computer-to-plate imaging solutions; press systems and components under the PROSPER brand name, as well as print inks and primers under the KODAK OPTIMAX, KODACHROME, and KODAK EKTACOLOR brand names; and PRINERGY, a workflow production software, which is used by customers to manage digital and conventional print content from file creation to output. This segment offers its products to commercial industries, including commercial print, direct mail, book publishing, newspapers and magazines, décor, and packaging/labels. The Advanced Materials and Chemicals segment engages in industrial film and chemicals, motion picture, advanced materials and functional printing, and IP licensing and analytical activities. This segment also comprises the Kodak Research Laboratories, which conducts research, develops new product or new business opportunities, and files patent applications for its inventions and innovations, as well as manages licensing of its intellectual property to third parties. The Brand segment engages in the licensing of Kodak brand to third parties. The company is also involved in the operation of Eastman Business Park, a technology center and industrial complex. It sells its products and services through direct sales, third party resellers, dealers, channel partners, and distributors. The company was founded in 1880 and is headquartered in Rochester, New York.
Receive News & Ratings for Amarillo Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarillo Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
